These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 27584910)

  • 1. Effect of decision aid for breast cancer prevention on decisional conflict in women with a BRCA1 or BRCA2 mutation: a multisite, randomized, controlled trial.
    Metcalfe KA; Dennis CL; Poll A; Armel S; Demsky R; Carlsson L; Nanda S; Kiss A; Narod SA
    Genet Med; 2017 Mar; 19(3):330-336. PubMed ID: 27584910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effectiveness of evidence-based decision aids for women with pathogenic BRCA1 or BRCA2 variants in the german health care context: results from a randomized controlled trial.
    Kautz-Freimuth S; Redaèlli M; Shukri A; Kentenich H; Simic D; Mildenberger V; Schmutzler R; Rhiem K; Stock S
    BMC Med Inform Decis Mak; 2023 Oct; 23(1):223. PubMed ID: 37845719
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Longitudinal changes in patient distress following interactive decision aid use among BRCA1/2 carriers: a randomized trial.
    Hooker GW; Leventhal KG; DeMarco T; Peshkin BN; Finch C; Wahl E; Joines JR; Brown K; Valdimarsdottir H; Schwartz MD
    Med Decis Making; 2011; 31(3):412-21. PubMed ID: 20876346
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of a computer-based decision aid on knowledge, perceptions, and intentions about genetic testing for breast cancer susceptibility: a randomized controlled trial.
    Green MJ; Peterson SK; Baker MW; Harper GR; Friedman LC; Rubinstein WS; Mauger DT
    JAMA; 2004 Jul; 292(4):442-52. PubMed ID: 15280342
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of a decision aid for BRCA1/BRCA2 mutation carriers: impact on measures of decision making and satisfaction.
    Schwartz MD; Valdimarsdottir HB; DeMarco TA; Peshkin BN; Lawrence W; Rispoli J; Brown K; Isaacs C; O'Neill S; Shelby R; Grumet SC; McGovern MM; Garnett S; Bremer H; Leaman S; O'Mara K; Kelleher S; Komaridis K
    Health Psychol; 2009 Jan; 28(1):11-19. PubMed ID: 19210013
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development and testing of a decision aid for breast cancer prevention for women with a BRCA1 or BRCA2 mutation.
    Metcalfe KA; Poll A; O'Connor A; Gershman S; Armel S; Finch A; Demsky R; Rosen B; Narod SA
    Clin Genet; 2007 Sep; 72(3):208-17. PubMed ID: 17718858
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of decision aids for female BRCA1 and BRCA2 mutation carriers: a systematic review.
    Krassuski L; Vennedey V; Stock S; Kautz-Freimuth S
    BMC Med Inform Decis Mak; 2019 Aug; 19(1):154. PubMed ID: 31370837
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation and evaluation of a nurse-led decision-coaching program for healthy breast cancer susceptibility gene (BRCA1/2) mutation carriers: a study protocol for the randomized controlled EDCP-BRCA study.
    Isselhard A; Töpper M; Berger-Höger B; Steckelberg A; Fischer H; Vitinius F; Beifus K; Köberlein-Neu J; Wiedemann R; Rhiem K; Schmutzler R; Stock S
    Trials; 2020 Jun; 21(1):501. PubMed ID: 32513307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of two evidence-based decision aids for female BRCA1/2 mutation carriers in Germany: study protocol for a randomised controlled parallel-group trial.
    Kautz-Freimuth S; Redaèlli M; Isselhard A; Shukri A; Vodermaier A; Rhiem K; Schmutzler R; Stock S
    Trials; 2022 Feb; 23(1):157. PubMed ID: 35172875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of knowledge and knowledge gain after decision aid use among women with BRCA1/2 pathogenic variants.
    Lautz Z; Kautz-Freimuth S; Shukri A; Redaèlli M; Rhiem K; Schmutzler R; Stock S
    Patient Educ Couns; 2024 Jul; 124():108248. PubMed ID: 38513456
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Behavioral and psychosocial effects of rapid genetic counseling and testing in newly diagnosed breast cancer patients: design of a multicenter randomized clinical trial.
    Wevers MR; Ausems MG; Verhoef S; Bleiker EM; Hahn DE; Hogervorst FB; van der Luijt RB; Valdimarsdottir HB; van Hillegersberg R; Rutgers EJ; Aaronson NK
    BMC Cancer; 2011 Jan; 11():6. PubMed ID: 21219598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Information needs of mothers regarding communicating BRCA1/2 cancer genetic test results to their children.
    Tercyak KP; Peshkin BN; Demarco TA; Patenaude AF; Schneider KA; Garber JE; Valdimarsdottir HB; Schwartz MD
    Genet Test; 2007; 11(3):249-55. PubMed ID: 17949286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of rapid genetic testing for BRCA1 and BRCA2 at time of breast cancer diagnosis on psychosocial functioning.
    Metcalfe KA; Eisen A; Wright F; Poll A; Candib A; McCready D; Cil T; Armel S; Silberman Y; Brennenstuhl S; Narod SA
    Breast Cancer Res Treat; 2022 Feb; 191(3):631-641. PubMed ID: 34846626
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and emotional factors predicting decisional conflict among high-risk breast cancer survivors who receive uninformative BRCA1/2 results.
    Rini C; O'Neill SC; Valdimarsdottir H; Goldsmith RE; Jandorf L; Brown K; DeMarco TA; Peshkin BN; Schwartz MD
    Health Psychol; 2009 Sep; 28(5):569-578. PubMed ID: 19751083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. How should we discuss genetic testing with women newly diagnosed with breast cancer? Design and implementation of a randomized controlled trial of two models of delivering education about treatment-focused genetic testing to younger women newly diagnosed with breast cancer.
    Watts KJ; Meiser B; Mitchell G; Kirk J; Saunders C; Peate M; Duffy J; Kelly PJ; Gleeson M; Barlow-Stewart K; Rahman B; Friedlander M; Tucker K;
    BMC Cancer; 2012 Jul; 12():320. PubMed ID: 22838957
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Systematic review of the empirical investigation of resources to support decision-making regarding BRCA1 and BRCA2 genetic testing in women with breast cancer.
    Grimmett C; Pickett K; Shepherd J; Welch K; Recio-Saucedo A; Streit E; Seers H; Armstrong A; Cutress RI; Evans DG; Copson E; Meiser B; Eccles D; Foster C
    Patient Educ Couns; 2018 May; 101(5):779-788. PubMed ID: 29225062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRCA1/2 testing in hereditary breast and ovarian cancer families: effectiveness of problem-solving training as a counseling intervention.
    McInerney-Leo A; Biesecker BB; Hadley DW; Kase RG; Giambarresi TR; Johnson E; Lerman C; Struewing JP
    Am J Med Genet A; 2004 Oct; 130A(3):221-7. PubMed ID: 15378542
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Testing of a Decision Aid for Unaffected Women with a BRCA1 or BRCA2 Mutation.
    Jabaley T; Underhill-Blazey ML; Berry DL
    J Cancer Educ; 2020 Apr; 35(2):339-344. PubMed ID: 30661232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Facilitating decision-making in women undergoing genetic testing for hereditary breast cancer: BRECONDA randomized controlled trial results.
    Sherman KA; Kilby CJ; Shaw LK; Winch C; Kirk J; Tucker K; Elder E
    Breast; 2017 Dec; 36():79-85. PubMed ID: 29031121
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Study protocol: a cluster randomized controlled trial of web-based decision support tools for increasing BRCA1/2 genetic counseling referral in primary care.
    Silverman TB; Vanegas A; Marte A; Mata J; Sin M; Ramirez JCR; Tsai WY; Crew KD; Kukafka R
    BMC Health Serv Res; 2018 Aug; 18(1):633. PubMed ID: 30103738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.